SHERIDAN, WYOMING -- July 10, 2026 -- The German Bundestag has passed the Healthcare Contribution Rate Stabilization Act, exempting supply-critical active pharmaceutical ingredients from an additional 8.5 percent manufacturer surcharge. The Plasma Protein Therapeutics Association Deutschland e.V. (PPTA) welcomed the legislative decision, which recognizes the unique production and supply realities of blood plasma products essential for patients with severe and rare diseases. The exemption addresses operational concerns about maintaining access to medications that cannot be synthetically manufactured and require seven to twelve months from donation to finished product.
Blood Plasma Products Excluded from 8.5 Percent Surcharge
Germany's parliament retained the exemption for supply-critical active ingredients when introducing the supplementary manufacturer surcharge. Blood plasma products appear on critical medicine lists maintained by the World Health Organization, the European Medicines Agency, and Germany's Federal Institute for Drugs and Medical Devices. These products serve patients with no therapeutic alternatives and support basic and crisis healthcare delivery. The exemption prevents additional financial pressure on a supply chain already operating under strain.
Production Complexity Limits Supply Flexibility
Blood plasma cannot be synthesized chemically. Production depends entirely on voluntary donations from human donors. Donation rates have stagnated while medical demand continues to grow. Europe already imports blood plasma from third countries including the United States to maintain adequate supply levels. Manufacturing timelines extend seven to twelve months from collection to finished medication. Raw material costs for blood plasma continue to rise, creating production expenses significantly higher than conventional pharmaceuticals.
Legislative Recognition Protects Patient Access
The exemption applies to medications classified as supply-critical under existing regulatory frameworks. PPTA Deutschland represents over 1,000 blood plasma donation centers across North America and Europe, including more than 70 facilities in Germany. Member companies produce approximately 50 percent of blood plasma products manufactured in Europe. The association emphasized that additional financial burdens would directly threaten patient access to irreplaceable therapies. Dr. Petros Gatsios, Chairman of PPTA Deutschland, stated the legislative decision demonstrates appropriate consideration for supply security and patient needs.
Donation Stagnation Meets Rising Medical Demand
Voluntary donor participation has not kept pace with increasing clinical requirements for plasma-derived therapies. The gap between supply and demand creates ongoing pressure on manufacturers and healthcare systems. Import dependency exposes European supply chains to external market dynamics and regulatory variations. Production facilities cannot rapidly scale output due to biological constraints and quality control requirements. Each batch requires extensive testing and processing steps mandated by pharmaceutical regulations.
Material Costs Exceed Conventional Drug Production
Raw material acquisition for blood plasma products involves donor compensation, collection infrastructure, and cold chain logistics. These fixed costs differ fundamentally from chemical synthesis operations. Processing facilities must maintain specialized equipment and trained personnel for biological material handling. Quality assurance protocols add time and expense beyond standard pharmaceutical manufacturing. The cost structure makes blood plasma products particularly sensitive to additional financial impositions like manufacturer surcharges.
Industry Association Advocates for Continued Policy Recognition
PPTA Deutschland stated it will continue working to ensure future healthcare legislation accounts for the distinct characteristics of supply-critical medications. The association sets global standards for quality and safety in blood plasma donation and processing. Member companies operate under regulatory frameworks that prioritize patient safety and product reliability. The organization emphasized that maintaining stable production conditions directly affects patient outcomes for individuals dependent on plasma-derived therapies with no substitutes available.
Healthcare purchasers, hospital administrators, and policy professionals seeking information about blood plasma product supply dynamics and regulatory considerations can visit the Plasma Protein Therapeutics Association at https://www.pptaglobal.org